Following are answers to some of the questions asked by journalists. For more information about our work, please visit the pages on this site focused on our medicines, research, mission and corporate responsibility initiatives.


  • Who is Gilead?

    Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need.

  • How many products does Gilead currently market?

    Our product portfolio currently comprises 15 marketed treatments. These include a number of category firsts and market leaders in the following therapeutic areas: HIV/AIDS; hepatitis; serious respiratory and cardiovascular conditions; cancer and inflammation.

  • How large is Gilead?

    Gilead has approximately 5,000 employees.

  • Are logos and photos of Gilead and Gilead’s products available?

    Photos and logos of Gilead and our products are available. We ask that you make your request by contacting the Public Affairs office at (650) 574-3000 or via email at public_affairs@gilead.com.

  • Do you have b-roll and manufacturing footage available?

    Yes, we have broadcast-quality b-roll available for journalists. We ask that you make your request by contacting the Public Affairs office at (650) 574-3000 or via email at public_affairs@gilead.com.

  • Where is Gilead's headquarters?

    Gilead's headquarters are located at 333 Lakeside Drive, Foster City, CA, 94404. The main phone number is (800) 445-3235 or (650) 574-3000.

  • I’m working on a story about Gilead and would like to arrange an interview with a Gilead spokesperson. How do I go about that?

    Please contact Gilead’s Public Affairs office at (650) 574-3000 or via email at public_affairs@gilead.com.

  • Where is Gilead incorporated?

    Gilead is incorporated in the State of Delaware.

  • When did Gilead go public?

    Gilead went public in January 1992.

  • What were the company’s total product sales in 2012? Non-GAAP R&D expenses? Non-GAAP SG&A expenses? Non-GAAP Net income and EPS?

    Total net product sales in 2012 were $9.40 billion. Non-GAAP R&D expenses were $1.50 billion and Non-GAAP SG&A were $1.23 billion. Non-GAAP net income was $3.08 billion or $1.95 EPS per fully diluted share.